Join to View Full Profile
8900 Wilshire BlvdBeverly Hills, CA 90211
Phone+1 310-432-8900
Fax+1 310-432-8901
Dr. Gabayan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Olive View/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1998 - 2001
UCLA-VA Greater Los AngelesResidency, Internal Medicine, 1994 - 1997
Keck School of Medicine of the University of Southern CaliforniaClass of 1994
Certifications & Licensure
CA State Medical License 1996 - 2027
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2013
Clinical Trials
- Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC Start of enrollment: 2019 Sep 20
Publications & Presentations
PubMed
- 215 citationsElranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.Alexander M Lesokhin, Michael H Tomasson, Bertrand Arnulf, Nizar J Bahlis, H Miles Prince
Nature Medicine. 2023-09-01 - 33 citationsA Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab‐Paclitaxel and Gemcitabine in Advanced Solid TumorsGregory L. Beatty, Safi Shahda, Thaddeus Beck, Nikhil Uppal, Steven J. Cohen
The Oncologist. 2019-01-01 - 35 citationsExtended follow‐up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myelomaSundar Jagannath, Brian G.M. Durie, Jeffrey L. Wolf, Elber Camacho, David Irwin
British Journal of Haematology. 2009-09-01
Press Mentions
Kiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01January 21st, 2025- Kiromic BioPharma Partners with Beverly Hills Cancer Center for Groundbreaking Lung Cancer Study, USOctober 24th, 2023
- Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial AgreementOctober 25th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
